Jara-Palomares, LuisBikdeli, BehnoodJimenez, DavidMuriel, AlfonsoMartin-Del-Pozo, MarDemelo-Rodriguez, PabloMonreal, Manuel2023-05-032023-05-032022Jara-Palomares L, Bikdeli B, Jiménez D, Muriel A, Martin Del Pozo M, Demelo-Rodríguez P, et al. Rate of Recurrence After Discontinuing Anticoagulation Therapy in Patients With COVID-19-Associated Venous Thromboembolism. JAMA Intern Med. 2022 Dec 1;182(12):1326-1328.http://hdl.handle.net/10668/19507This prospective, multinational cohort study used data from the Registro Informatizado de la Enfermedad Tromboembolica (RIETE) registry , which prospectively collects information on patients with VTE.4 Since March 25, 2020, RIETE has incorporated data on COVID-19–associated VTE. This study included patients who developed proximal deep vein thrombosis (DVT) and/or pulmonary embolism (PE) within 30 days of confirmed COVID-19 between March 25, 2020, and April 23, 2021, and discontinued AT after at least 3 months (eMethods in the Supplement). 1-3 Patients with upper limb or unusual sites of DVT, those who did not receive at least 3 months of AT, and those who were followed up for less than 15 days after AT discontinuation were excluded. The observation period for the inception cohort began on the day of AT discontinuation and ended with recurrent VTE, death , or on November 24, 2021. This study was approved by the Ethics Committee of Hospital Germans Trias i Pujol. Oral informed consent was obtained. This study followed the STROBE reporting guideline .enCohort StudiesVenous ThrombosisUpper ExtremityRegistriesPulmonary EmbolismHumansHumansVenous ThromboembolismCOVID-19AnticoagulantsRecurrenceRisk Factorsresearch article36342711Restricted AccessPacientesTrombosis de la VenaNotificaciónExtremidad superiorEmbolia pulmonarHospitales10.1001/jamainternmed.2022.49542168-6114PMC9641587https://jamanetwork.com/journals/jamainternalmedicine/articlepdf/2797777/jamainternal_jarapalomares_2022_ld_220038_1670009042.10942.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9641587/pdf